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Abstract
Background
Use of selective COX-2 non-steroidal anti-inflammatory drugs (NSAIDs) (coxibs) has been
associated with an increased risk of acute myocardial infarction (AMI). However, the risk of
AMI has only been studied for very few NSAIDs that are frequently used.
Objectives
To estimate the risk of AMI for individual NSAIDs.
Methods
A nested case-control study was performed from a cohort of new NSAID users�18 years
(1999–2011) matching cases to a maximum of 100 controls on database, sex, age, and cal-
endar time. Data were retrieved from six healthcare databases. Adjusted odds ratios (ORs)
of current use of individual NSAIDs compared to past use were estimated per database.
Pooling was done by two-stage pooling using a random effects model (ORmeta) and by
one-stage pooling (ORpool).
Results
Among 8.5 million new NSAID users, 79,553 AMI cases were identified. The risk was ele-
vated for current use of ketorolac (ORmeta 2.06;95%CI 1.83–2.32, ORpool 1.80; 1.49–
2.18) followed, in descending order of point estimate, by indometacin, etoricoxib, rofecoxib,
diclofenac, fixed combination of diclofenac with misoprostol, piroxicam, ibuprofen,
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naproxen, celecoxib, meloxicam, nimesulide and ketoprofen (ORmeta 1.12; 1.03–1.22,
ORpool 1.00;0.86–1.16). Higher doses showed higher risk estimates than lower doses.
Conclusions
The relative risk estimates of AMI differed slightly between 28 individual NSAIDs. The rela-
tive risk was highest for ketorolac and was correlated with COX-2 potency, but not restricted
to coxibs.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to reduce inflammation and
provide pain relief. They act via reversible, competitive inhibition of cyclo-oxygenase (COX)
enzymes. As inhibition of the COX-1 enzyme decreases prostaglandins production, gastroin-
testinal adverse events including ulcerations and bleeding occur often during NSAID use. This
led to development of selective COX-2 inhibitors (coxibs) which after successful market intro-
duction [1,2] were considered with cardiovascular safety resulting in the voluntary withdrawal
of rofecoxib in 2004.[3] The underlying mechanism of increased cardiovascular events may be
related to a dysbalance in COX-1 and COX-2 inhibition properties favoring thrombosis by
vasoconstriction and platelet aggregation.[4,5]
Reviews by the United States Food and Drug Administration and the European Medicines
Agency (EMA) concluded that coxibs increase the risk of CV events.[6,7] It was recom-
mended, for instance by the American Heart Association, in 2005 to avoid the use of coxibs in
patients with ischemic heart disease, stroke or peripheral arterial disease.[7–10] At that
moment little information was available about the CV risk of NSAIDs, but further studies
showed signals of increased arterial thrombosis risk for non-selective (ns) NSAIDs, particu-
larly when used in high doses and for long-term.[4,11] Based on the uncertainty, EMA
requested a review of the CV safety of nsNSAIDs as well, which resulted in the Non-Steroidal
Anti-inflammatory Drugs (SOS) project.[12] Previously published meta-analyses of clinical
trials[13] or from observational studies reported on increased risks of composite cardiovascu-
lar endpoints for only a few traditional NSAIDs and coxibs.[14] This SOS study aimed to assess
and summarize the risk of acute myocardial infarction (AMI) associated with the use of a large
variety of individual NSAIDs in Europe.
Material and methods
Study design and data sources
A nested case-control study was conducted within a cohort of new NSAID users during the
study period.
Data for this study was obtained from six different longitudinal population-based health
care databases from four European countries (GePaRD from Germany (GE), OSSIFF and
SISR from Italy (IT), IPCI and PHARMO from the Netherlands (NL) and THIN from the
United Kingdom (UK)) covering a source population of around 32 million subjects. All data-
bases have been used for pharmacoepidemiological research (S1 Table)[15–18] and are
described detailed in previous publications.[19,20]
The German Pharmacoepidemiological Research Database (GePaRD) is a database com-
prising data from five statutory health insurance companies throughout Germany and
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currently covers around 14 million persons representing approximately 20% of the popula-
tion.[17] The Health Improvement Network (THIN) database is a general practice (GP) data-
base in the UK and currently captures medical records of 11.1 million patients.[16,21] The
Integrated Primary Care Information (IPCI) database is a GP database from the Netherlands
and currently covers over 1.5 million people [18], PHARMO database is a medical record link-
age system of 2.2 million community-dwelling inhabitants in the Netherlands.[15] OSSIFF
(Osservatorio Interaziendale per la Farmacoepidemiologia e la Farmacoeconomia) is a data-
base capturing national health service data and clinical registries from several local health
agencies in Lombardy) for a population of about 2.9 million people. The second Italian data-
base SISR (Sistema Informativo Sanitario Regionale) obtains national health service data from
the Lombardy region, with about nine million inhabitants (approximately 16% of the national
population). To avoid overlap the OSSIFF population was removed from the SISR database.
All GP and claims databases contain information on demographics of the population, diag-
noses (in- and/or outpatient), and drug prescriptions/dispensings. The diagnoses captured by
the databases are coded with four disease coding systems including the International Classifi-
cation of Diseases (ICD) 9th or 10th revision [22], International Classification for Primary Care
(ICPC)[23], or READ.[24] Mapping of concepts and codes was performed using the Unified
Medical Language System (UMLS), according to a previously described workflow.[25,26] All
drugs were mapped to the World Health Organization’s (WHO) Anatomical Therapeutic
Chemical classification.[27] A distributed approach was used for collaboration: all database
custodians extracted data locally; original data were transformed into a common data model;
codes for outcome and covariates were mapped using an extensive harmonization strategy;
and a common standardized script (Jerboa, Erasmus University Medical Center)[28] was used
to create aggregated tables that were subsequently encrypted and shared on a central data
warehouse for further analysis. [19,20,28]
Study cohort
In each database, we identified a cohort of patients aged�18 years who received at least one
new NSAID prescription (S2 Table) during the database-specific study period within the gen-
eral study period which started 1 January 1999 and ended 31 December 2011 (S1 Table).
Cohort entry was the date of first NSAID prescription/dispensation during the study
period. Patients were excluded if they received any NSAID prescription in the year before to
avoid prevalent user bias.[29] Patients needed to have at least one year of continuous database
history to allow assessment of confounders and exclusion criteria. All subjects with a cancer
diagnosis (except non-melanoma skincancer) during the one year preceding cohort entry
were excluded from the cohort. All NSAID cohort members were followed from the date of
cohort entry until date of AMI diagnosis, cancer, death, last data supply, transferring out of the
database, or end of the study period, whichever was earliest.
Cases and controls
The outcome was a first hospitalization with a discharge diagnosis code of AMI (GePaRD,
PHARMO, OSSIFF, and SISR) or a first diagnosis of AMI (THIN and IPCI) during follow-up
(S3 Table for codes). In OSSIFF a sample of hospitalization codes were validated against the
hospitalization records (PPV 89%; 95%CI: 77–96). In IPCI all cases were validated. PPVs of
codes used to identify AMI in the current study ranged between 95% (ICD-9CM) and 100%
(ICD-10) in previous studies.[30,31] The date of recorded diagnosis or admission date of AMI
was used as index date. Within each database, up to 100 controls were matched on the index
Risk of acute myocardial infarction with NSAIDs
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date (‘event’ date) to each case by risk set sampling on age (± 1 year), sex and cohort entry (±
28 days).
NSAID-exposure
Exposure to individual NSAIDs was obtained from prescriptions or from outpatient drug dis-
pensings claims. Duration was obtained by dividing the total units by the daily number of
units prescribed (THIN, IPCI, and PHARMO: prescribed duration), for other databases stan-
dard durations were used based on the country specific defined daily dose (DDD) values.[32]
Mean duration of NSAID use in the cohort is shown in S8 Table.
Recency of exposure to individual NSAIDs was classified using the interval between index
date and the end of the most recent NSAID use before the index date: 1)�14 days before
index date classified as ‘current’ use; 2) between 15 and 183 days before index date as ‘recent’
and; 3)�184 days before index date as ‘past’. Exposure periods were considered mutually
exclusive. Duration of current use was then classified into very short (1–6 days), short (7–29),
medium (30–89) and long (� 90). If multiple NSAIDs were used in the current period, NSAID
use was assigned to current use of all NSAIDs. We assigned current exposure to the most
recent NSAID used prior to index date if patients switched between NSAIDs. Past use of any
NSAID was considered as common reference group in order to compare across NSAIDs.
In IPCI, THIN and PHARMO daily dose of NSAID was estimated from the prescribing
regimen and strength. Dose of current exposure to each individual NSAID was classified using
the ratio of prescribed daily dose (PDD) compared to DDD in order to allow for comparison
across NSAIDs, daily dose was categorized as low dose (<0.8 PDD/DDD), normal dose (0.8–
1.2 PDD/DDD) and high dose (�1.3 PDD/DDD) (S4 Table).
Covariates
Covariates were classified into a-priori risk factors (history of ischemic heart disease (exclud-
ing AMI); history of stroke; heart failure; diabetes mellitus type 2; hyperlipidemia; smoking;
use of ACE inhibitors, antithrombotic agents, low-dose aspirin, beta blockers, calcium channel
blockers, diuretics, glucocorticoids, nitrates, oral contraceptives, platelet aggregation inhibi-
tors, lipid lowering drugs and postmenopausal hormone therapy) or potential confounders
(obesity, osteoarthritis and use of anticoagulants). They were measured during the 12 months
prior to cohort entry or in 30 or 90 days before index date.
Statistical analyses
To estimate the risk for AMI among current use of an individual NSAID in comparison to
past use of any NSAID, odds ratios were calculated using conditional logistic regression analy-
ses for each database separately if five or more exposed cases per database were available. Com-
bining data from several sources is possible in mainly two ways: 1) one-stage analysis; which
consists of performing the analysis on one large database where individual patient-level data
from different databases is pooled; or 2) two stage meta-analysis; in which the analyses are per-
formed on each single database and the summary statistics are combined using standard meta-
analysis techniques. Two stage pooled NSAID-specific ORs (ORmeta) were calculated both
using fixed and random effects meta-analysis.[33,34] The degree of statistical heterogeneity
was measured by I2.[35] One stage pooling of data across databases was performed by combin-
ing the matched case control sets and analysis with conditional logistic regression adjusted for
covariates. This approach has most power and provides one overall risk measure (ORpooled)
for all NSAIDs with at least five exposed cases.
Risk of acute myocardial infarction with NSAIDs
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A stepwise approach was used for confounder selection in both approaches: 1) a-priori
selected confounders were always included; 2) univariate analyses for each potential con-
founder with a prevalence of 5% in controls, which were added to the model if Wald p-value
was<0.05; 3) backward selection of potential confounders (p-value>0.05).
Categorical duration analyses were performed within current users of each individual
NSAID, using short duration (7–29 days) as reference group. Dose analyses were done by cate-
gories comparing dose levels to past use of any NSAID and by continuous analyses through
restricted cubic splines (3 knots) and through fractional polynomial regression (maximum of
2 terms).[36] Since potency of COX-inhibition of NSAIDs is based on normal therapeutic
doses, the relationship between COX-2 potency and the relative risk of AMI was visualized by
plotting the relative risk results by the COX-2 inhibition using normal daily doses (PDD/DDD
between 0.8 and 1.2). [4]
Effect modification was investigated by stratification for sex, age (�60 or>60 years), prior
ischemic heart disease, use of aspirin or lipid lowering drugs and calendar year (�2004 or
>2004), we tested for multiplicative interaction. All analyses were performed using SAS (Cary,
NC version 9.2).
Results
The study cohort comprised 8,535,952 new NSAID users (S1 Fig), of whom 101,227 patients
developed an AMI after cohort entry. Of these, 79,553 (78.6%) cases could be matched to at
least one control. Baseline characteristics of cases and matched controls are shown in Table 1
and exposure in Table 2. If persons used multiple NSAIDs each individual NSAID was consid-
ered; 93–97% of current users used only one NSAID. Cases had more often risk factors for
AMI such as a prior history of ischemic heart disease, other cardiovascular diseases or use of
cardiovascular drugs, than controls but the prevalence of these risk factors did not differ
between different NSAID users (S6 Table).
Whereas UK, NL and Germany use similar NSAIDS, Italy uses quite a different range of
NSAIDs, for 11 individual NSAIDs data were only available from Italy (S5 Table) Meta-ana-
lytic estimates of the adjusted ORs across databases could be calculated for 21 NSAIDs. The
adjusted OR for current use ranged between 0.93 for oxaprozin to 2.06 for ketorolac (Fig 1,
Table 2), but the width of the confidence intervals vary. Ten NSAIDs were associated with a
statistically significantly increased risk. For 11 NSAIDs we did not observe a significant
increased association with AMI in the meta-analytic pooling approach for these NSAIDs the
upper 95% limits was below two. For most NSAIDs no heterogeneity was seen according to
the estimated I2 across databases (Table 2).
The one stage pooling (Fig 1, Table 2), yielded estimates for 28 individual NSAIDs, for
most NSAIDs the two and one stage pooled estimates were quite similar. Results of this com-
bined analysis showed that the risk of AMI is statistically significantly elevated for 12 NSAIDs.
Compared to past use of any NSAID the OR was highest for ketorolac, followed by indometa-
cin, etoricoxib and rofecoxib (Fig 1), though the 95% confidence limits overlap between these
NSAIDs. For 16 NSAIDs the association with AMI was not statistically significantly elevated,
but for four of those NSAIDs the 95%CI upper limits were above two. The relationship
between COX-2 potency and the risk of AMI for normal daily doses (PDD/DDD 0.8–1.2) is
seen in S2 Fig.
Categorical dose response analyses versus past use of any NSAID in the subset of databases
with prescription regimens (THIN, IPCI, PHARMO) showed that higher doses of celecoxib,
the fixed combination of diclofenac and misoprostol, etoricoxib and naproxen increased the
risk of AMI (Fig 2). Continuous dose-response curves with cubic splines showed a significant
Risk of acute myocardial infarction with NSAIDs
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dose response for diclofenac only (S3 Fig). For duration, no clear patterns were seen (S4 Fig).
The risk of AMI seemed highest with shortest duration for diclofenac, which was also seen for
ibuprofen and rofecoxib although confidence limits between categories overlapped.
Stratification by AMI risk factors for each NSAID did not reveal consistent patterns for
potential effect modifiers across individual NSAIDs (S7 and S9 Tables).
Discussion
In this unique multinational case-control study nested in a new user NSAID cohort of more
than 8.5 million persons, we assessed the association with AMI for 28 individual NSAIDs.
Table 2. Association between current use of an individual NSAID and risk of AMI compared with past use of any NSAID pooled by meta-analysis approach (ran-
dom and fixed effects) and by unweighted (matched set) pooled dataset.
Meta-analysis approach
(random effects)
Meta-analysis (fixed effects) Pooled dataset
Cases
N
Controls
N
Number of databases ORmeta
(95% CI)
I2 � ORfixed
(95% CI)
ORpooled
(95% CI)
Past Use of any NSAID 55,657 5,307,077 6 1 (ref) 1 (ref) 1 (ref)
Recent use of any NSAID 23,896 2,181,526 6 1.08 (1.04 to 1.11) 65.27 1.08 (1.06 to 1.09) 1.08 (1.06 to 1.11)
Current use of:
Aceclofenac 214 20,370 4 1.04 (0.90 to 1.19) 0.00 1.04 (0.9 to 1.19) 1.08 (0.85 to 1.36)
Acemetacin 14 1,178 1 1.00 (0.58 to 1.71)
Celecoxib 886 76,132 5 1.15 (0.91 to 1.46) 66.61 1.12 (1.05 to 1.20) 1.15 (1.05 to 1.25)
Dexibuprofen 41 2,651 2 1.15 (0.79 to 1.68) 0.00 1.15 (0.79 to 1.68) 1.06 (0.61 to 1.82)
Dexketoprofen 9 723 1 1.01 (0.50 to 2.04)
Diclofenac 3,064 230,213 6 1.31 (1.17 to 1.48) 60.03 1.32 (1.27 to 1.37) 1.28 (1.22 to 1.34)
Diclofenac, combinations 399 27,923 6 1.27 (1.11 to 1.44) 18.76 1.27 (1.15 to 1.40) 1.30 (1.17 to 1.45)
Etodolac 37 2,761 1 1.07 (0.76 to 1.50)
Etoricoxib 497 37,478 6 1.28 (1.17 to 1.40) 11.71 1.27 (1.16 to 1.39) 1.39 (1.24 to 1.57)
Flurbiprofen 27 1,972 2 1.05 (0.66 to 1.67) 0.00 1.05 (0.66 to 1.67) 1.00 (0.56 to 1.78)
Ibuprofen 1,564 119,219 6 1.24 (1.04 to 1.48) 61.38 1.25 (1.19 to 1.32) 1.25 (1.18 to 1.33)
Indometacin 196 11,789 5 1.47 (1.27 to 1.70) 0.00 1.47 (1.27 to 1.70) 1.51 (1.28 to 1.80)
Ketoprofen 559 47,969 3 1.12 (1.03 to 1.22) 0.00 1.12 (1.03 to 1.22) 1.00 (0.86 to 1.16)
Ketorolac 272 11,732 2 2.06 (1.83 to 2.32) 0.00 2.06 (1.83 to 2.32) 1.80 (1.49 to 2.18)
Lornoxicam 40 3,095 2 1.08 (0.77 to 1.51) 0.00 1.08 (0.77 to 1.51) 1.08 (0.62 to 1.87)
Mefenamic acid 12 981 1 1.02 (0.55 to 1.90)
Meloxicam 492 38,806 6 1.18 (1.08 to 1.29) 0.00 1.18 (1.08 to 1.29) 1.13 (1.02 to 1.27)
Nabumetone 46 3,795 4 1.03 (0.76 to 1.40) 0.00 1.03 (0.76 to 1.40) 1.03 (0.72 to 1.47)
Naproxen 486 38,659 6 1.19 (0.95 to 1.49) 47.10 1.18 (1.08 to 1.29) 1.22 (1.10 to 1.35)
Nimesulide 1,652 133,462 2 1.16 (1.11 to 1.22) 0.00 1.16 (1.10 to 1.22) 1.12 (1.03 to 1.22)
Oxaprozin 22 2,709 2 0.93 (0.63 to 1.38) 0.00 0.93 (0.63 to 1.38) 0.97 (0.52 to 1.79)
Piroxicam 636 51,898 5 1.17 (0.99 to 1.37) 34.02 1.20 (1.10 to 1.30) 1.27 (1.13 to 1.42)
Proglumetacin 11 930 1 1.00 (0.41 to 2.47)
Rofecoxib 690 51,674 4 1.26 (1.17 to 1.36) 0.00 1.26 (1.17 to 1.36) 1.30 (1.19 to 1.43)
Sulindac 11 494 1 1.01 (0.48 to 2.15)
Tenoxicam 32 3,104 2 1.02 (0.71 to 1.46) 0.00 1.02 (0.71 to 1.46) 0.99 (0.56 to 1.74)
Tiaprofenic acid 8 710 1.01 (0.49 to 2.10)
Valdecoxib 25 2,159 3 1.00 (0.66 to 1.52) 0.00 1.00 (0.66 to 1.52) 1.07 (0.58 to 1.99)
� A high level of heterogeneity is present with an I2 value above 75%.
https://doi.org/10.1371/journal.pone.0204746.t002
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Following rofecoxib’s withdrawal many single studies have been conducted using different
protocols and definitions.[4,11,37–39] Meta-analyses of these studies identified large variabil-
ity between studies and several methodological issues such as lack of information on dose
effects, and lack of estimates for less frequently used NSAIDs.[12,14,40] The SOS study is a
major leap forward from those regular meta-analyses of different studies because it combines
patient-level data that have been collected using a common data model, protocol, definitions,
data transformation and analysis.
The highest risk of AMI was observed for current use of ketorolac. Various other widely
used nsNSAIDs, such as indometacin, diclofenac, piroxicam, ibuprofen, naproxen, meloxicam
and nimesulide; and selective COX-2 inhibitors, such as etoricoxib, rofecoxib and celecoxib,
were associated with a small increase in risk of AMI.
Our risk estimates are lower (except for naproxen and etoricoxib) than the estimates from
meta-analyses of clinical trials[13] for six NSAIDs (celecoxib, diclofenac, etoricoxib, ibuprofen,
naproxen, rofecoxib) that have been studied in RCT meta-analyses. Explanation might be that
some of the large efficacy trials were done for comparison of gastro-intestinal effects, with
higher dosages than in everyday practice.[41] For nine NSAIDs for which we have evidence
from meta-analyses of observational studies the SOS estimates were within the width of the
CIs, providing reassurance about consistency.[12,13] Also, estimates are in line with an indi-
vidual patient data meta-analysis for celecoxib, rofecoxib, diclofenac, ibuprofen and naproxen.
[14]
What are the key findings for individual nsNSAIDs in this study that are new and relevant
for clinicians? First, diclofenac (median dose 150 mg, 1.5 DDD) is very frequently used and
associated with AMI in a similar magnitude as rofecoxib (median dose 25 mg, 1 DDD). Recent
studies confirm this. [12–14] With support of SOS data, EMA had decided in 2013 to restrict
the use of diclofenac.[42] Second, there was one nsNSAID with even higher relative risk of
AMI: ketorolac, which was only used in Italy. The third finding is that we observed a 22%
increase in risk of AMI with naproxen use, which is in contrast with some previous studies
[11–13,37,43,44] but in line with others.[11,14,43,45–47] Prior studies showed an increase in
risk between 14%[46]-19%[47] for naproxen as compared to remote NSAID use, a similar
comparator group we used. Although trials provide higher level evidence for the specific study
population, our finding on naproxen is in line with some clinical trials.[48,49] In the TARGET
trial no significant differences were observed between the different NSAIDs and the incidence
of AMI.[49] Additionally in patients free of CV disease, rate of CV disease was similar for cele-
coxib as with nsNSAIDs.[50] A recent meta-analysis of individual patient data investigated
only five NSAIDs (celecoxib, rofecoxib, ibuprofen, diclofenac and naproxen) and showed that
compared to no use of NSAIDs in the previous year, the adjusted ORs were in line with our
results (Table 3).[14] Also, it demonstrated that the risk of AMI for celecoxib was comparable
to that of nsNSAIDs including naproxen. However, in the meta-analysis they used as reference
group no use of NSAID in the previous year, which explains the higher risks observed than in
our study.[14] Additionally, our findings regarding naproxen may be explained by differences
in dosing. In the dose response analyses that included UK and Dutch databases, the OR was
only statistically significantly increased for the highest dose of naproxen as compared to past
use of any NSAID and the median dose for naproxen was 2 times the daily recommended
dose, whereas other NSAIDs were prescribed lower doses (S4 Table).
Fig 1. Adjusted risk estimates of AMI for current use of individual NSAIDs versus past use of any NSAID in the pooled
analysis plotted in descending order from the NSAID with highest point estimate without taking the confidence limits
into account 1) meta-analytic pooling by random effects model and 2) on individual datasets.
https://doi.org/10.1371/journal.pone.0204746.g001
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Fig 2. Adjusted risk estimates for AMI in current users for dose of use of individual NSAIDs in three databases pooled (THIN, IPCI, PHARMO), using past use
of any NSAID as common reference group. PDD, prescribed daily dose; DDD, defined daily dose. Number of exposed cases do not add up to all current users of that
particular NSAID in all three databases pooled as dose information could have been missing.
https://doi.org/10.1371/journal.pone.0204746.g002
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The key findings related to coxibs are that the relative risk of AMI for etoricoxib was higher
than for diclofenac and almost equal to that for rofecoxib, though the CIs were overlapping. An
increased risk for etoricoxib was also found in the meta-analysis of observational studies.[12]
Although etoricoxib has not been studied extensively in placebo-controlled trials, effects of etori-
coxib, rofecoxib and celecoxib seemed similar in trials comparing COX-2 selective inhibitors to
Table 3. Risk estimates of AMI for individual NSAIDs from current SOS study, meta-analysis from observational studies[12] and randomized clinical trials[13],
using major vascular events as outcome.
SOS study (pooled
dataset)
Meta-analysis published
observational studies
Composite Endpoint from meta-analysis of
randomized clinical trials#
Meta-analysis individual
patient data†
Adjusted ORpooled
(95% CI)
Relative Risk (random effects) Adjusted Rate Ratio Adjusted odds ratio
Reference group Past Use of any
NSAID
No or remote NSAID use Placebo No use of NSAID in
previous year
Current use of:
Aceclofenac 1.08 (0.85 to 1.36)
Acemetacin 1.00 (0.58 to 1.71)
Celecoxib 1.15 (1.05 to 1.25) 1.23 (1.00 to 1.52)� 1.36 (0.91−2.02) 1.24 (0.91–1.82)
Dexibuprofen 1.06 (0.61 to 1.82)
Dexketoprofen 1.01 (0.50 to 2.04)
Diclofenac 1.28 (1.22 to 1.34) 1.41 (1.08 to 1.86)� 1.41 (1.12 to 1.78) 1.50 (1.06–2.04)
Diclofenac,
combinations
1.30 (1.17 to 1.45)
Etodolac 1.07 (0.76 to 1.50) 1.55 (1.16 to 2.06)
Etoricoxib 1.39 (1.24 to 1.57) 1.97 (1.35 to 2.89) 0.83 (0.18−3.77)
Flurbiprofen 1.00 (0.56 to 1.78)
Ibuprofen 1.25 (1.18 to 1.33) 1.20 (0.97 to 1.48)� 1.44 (0.89−2.33) 1.48 (1.00–2.26)
Indometacin 1.51 (1.28 to 1.80) 1.40 (1.21 to 1.62)
Ketoprofen 1.00 (0.86 to 1.16)
Ketorolac 1.80 (1.49 to 2.18)
Lornoxicam 1.08 (0.62 to 1.87)
Mefenamic acid 1.02 (0.55 to 1.90)
Meloxicam 1.13 (1.02 to 1.27) 1.25 (1.04 to 1.49)
Nabumetone 1.03 (0.72 to 1.47)
Naproxen 1.22 (1.10 to 1.35) 0.85 (0.73 to 1.00)� 0.93 (0.69−1.27) 1.53 (1.07–2.33)
Nimesulide 1.12 (1.03 to 1.22)
Oxaprozin 0.97 (0.52 to 1.79)
Piroxicam 1.27 (1.13 to 1.42)
Proglumetacin 1.00 (0.41 to 2.47)
Rofecoxib 1.30 (1.19 to 1.43) 1.43 (1.21 to 1.66)� 1.38 (0.99−1.94) 1.58 (1.07–2.17)
Sulindac 1.01 (0.48 to 2.15)
Tenoxicam 0.99 (0.56 to 1.74)
Tiaprofenic acid 1.01 (0.49 to 2.10)
Valdecoxib 1.07 (0.58 to 1.99)
� in new users exposed to NSAIDs
# The outcome major vascular events included non-fatal MI, coronary death, MI or CHD death, non-fatal stroke, stroke death, any stroke and other vascular death).
Daily dose studied in Clinical Trials: Diclofenac (150 mg); Ibuprofen (2400 mg); Naproxen (1000 mg); Celecoxib (100–800 mg, typical doses contributing the majority
of information on major vascular events 400 mg); Rofecoxib (12.5–125 mg; typical dose 25 mg); Lumiracoxib (100–800 mg; typical dose 200 mg); Etoricoxib (5–120 mg;
typical dose 60/90 mg); Valdecoxib (1–80 mg; typical dose 20 mg)
† current use is classified as use of any dose for 1–7 days
https://doi.org/10.1371/journal.pone.0204746.t003
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diclofenac.[13] In the MEDAL trial the rate of thrombotic cardiovascular events was similar
between the diclofenac and the etoricoxib group (HR 0.95; 95%CI:0.81–1.11), confirming our find-
ings.[51] Our results regarding celecoxib are consistent with the meta-analysis of observational
studies and show only a very small increase in risk.[12] Also, a recent published trial showed that
celecoxib is noninferior to ibuprofen and naproxen for cardiovascular safety.[48]
Dose response analyses showed that AMI risk varied by dose, which means that the overall
estimates are largely driven by the dose that will be used in a country. Lower doses generally,
but not for all drugs, have a lower risk in the databases we could use to study this. When plot-
ting the potency of individual NSAIDs in the degree of COX-2 inhibition by normal therapeu-
tic doses, it may seem to show a correlation in line with a previous study but we could only
look at 6 different NSAIDs as we needed daily dose information which was available in THIN,
IPCI and PHARMO.[4] This supports the previously suggested hypothesis that the extent of
inhibition of COX-2–dependent prostacyclin may represent an independent determinant of
the increased risk of nonfunctional suppression of platelet COX-1.[5] However, as the degree
of relative COX-1 and COX-2 inhibition varies between NSAIDs and between the non-selec-
tive and selective COX-2 inhibitors one may expect this suppression for all NSAIDs.[4]
Stratification for concurrent use of aspirin, lipid lowering drugs, presence of ischemic heart
disease, sex, and age several significant interactions were observed with isolated NSAIDs. E.g.
the risk for AMI associated with diclofenac was higher in females than males. The risk was sta-
tistically significantly higher in younger persons (<60 years) than older for naproxen. Our
findings are consistent with published findings showing that the relative risk of AMI in current
users of NSAIDs is higher in low-CV risk subjects, than in high-risk subjects. However, it
should be considered that the absolute risk is much higher in high-CV risk patients due to
higher background rates. [11–13,43]
Strength of the current study is the common distributed approach for collaboration[28] which
allowed us to analyze the data on one stage and two stage pooling being able to more stratified and
detailed analysis in one stage pooling while preserving differences in confounder availability by
two stage pooling.[52] Another method to summarize individual-level data from a large number of
covariates by calculating a propensity score, however although it allows for consistency of adjust-
ment for common confounders across the data sites, it does not fully use additional confounder
information that may be available at certain data sites. The final obtained exposure estimates in
each of the data sites should still be summarized in a summary and overall statistic.[53] We
acknowledge the following limitations. Since NSAID use was assessed through computerized pre-
scriptions/dispensing by physicians, over-the-counter NSAID use was not captured. Channeling of
COX-2 inhibitors to high GI-risk patients might have occurred and was addressed by matching on
calendar time beyond age, sex and database. Additionally, we adjusted for a large range of known
risk factors for AMI. The matched and adjusted estimates were very similar, indicating that most
of the potential confounding variables were time, sex and age-related and taken care of by the
matching. Moreover, we stratified by calendar time and saw no significant difference, also the prev-
alence of risk factors did not change before and after 2004. Restriction of the population to patients
without risk factors (where no channeling would occur) did not change the conclusions (S9
Table), although any remaining residual confounding or confounding by indication may be pres-
ent and resulted in biasing the results. Although dose analysis was performed to verify dose-
response relationships for NSAIDs and for comparison across NSAIDs independent of dosage
used, we only had dose available in three databases (THIN, IPCI, PHARMO) which is a limitation
of our study. We were not able to match all potential AMI cases to controls in the new NSAID
user cohort, due to the different matching criteria that were applied to limit confounding by calen-
dar time, age, sex and database site, this improves internal validity but potentially limits external
validity, most likely in patients at extreme age ranges.
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Concluding, this study provides risk estimates for the association between the use of 28 dif-
ferent NSAIDs and the risk of AMI. Evaluating the variability of AMI risk across these NSAIDs
in real life practice circumstances showed that for twelve individual NSAIDs the risk of AMI is
significantly increased and sixteen NSAIDs there was no significantly increased risk. Although
COX-2 potency is correlated with risk, it is not a strong feature determining the cardiovascular
safety of NSAIDs as was initially advocated. This should warrant doctors and pharmacists
when prescribing or dispensing NSAIDs to patients at CV risk.
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